NCT05402423

Brief Summary

JDOME is a randomized controlled trial to test the effectiveness of a computerized cognitive training with the Brainer web platform and aerobic training with the JDOME system vs. a computerized cognitive training with the Brainer web platform and aerobic training with a standard exercise bike in subjects with Alzheimer's Disease at early stage. The JDome BikeAround is a tool that take people with dementia on a virtual bicycle tour along the paths of memories. It combines an exercise bike, a dome-shaped projector and Google Street View technology.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2022

Shorter than P25 for not_applicable alzheimer-disease

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 30, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 2, 2022

Completed
25 days until next milestone

Study Start

First participant enrolled

June 27, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 26, 2023

Completed
Last Updated

October 26, 2023

Status Verified

October 1, 2023

Enrollment Period

12 months

First QC Date

May 30, 2022

Last Update Submit

October 24, 2023

Conditions

Keywords

Alzheimer Diseasevirtual systemaerobic exercisecognitive trainingdementiaquality of life

Outcome Measures

Primary Outcomes (2)

  • change in cognitive impairment

    Mini-Mental State Examination was designed as a clinical method for grading cognitive impairment. The score ranges from 0 to 30: scores ≥ 24 indicate normality, between 18-23 indicate mild cognitive impairment, between 11-17 moderate cognitive deficits, scores ≤ 10 severe cognitive impairments. The reported score will be corrected according to age and education.

    baseline, 8, and 22 weeks later

  • change in short and medium term memory

    Alzheimer's Disease Assessment Scale (ADAS-cog) consists of 11 items that investigate: short and medium term memory, language, praxia (simple, constructive, ideational), temporal-spatial orientation. The score ranges from 0 (no cognitive impairment) to 70 (maximum cognitive impairment).

    baseline, 8 and 22 weeks later

Secondary Outcomes (4)

  • change in quality of life

    baseline and 8, 22 weeks later

  • change in physical performance

    baseline, 8 and 22 weeks later

  • change in signs and symptoms of major depression

    baseline, 8 and 22 weeks later

  • change in neuropsychiatric disturbances

    baseline, 8 and 22 weeks later

Study Arms (2)

JDome rehabilitation group

EXPERIMENTAL

Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with the JDome System

Device: Computerized cognitive training plus aerobic exercise with the JDome System

control group

ACTIVE COMPARATOR

Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with standard exercise bike

Device: Computerized cognitive training plus aerobic exercise with standard exercise bike

Interventions

Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks). Each session will involve the following activities: * 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia * 30 minutes of aerobic training with the JDOME system,

JDome rehabilitation group

Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks). Each session will involve the following activities: * 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia * 30 minutes of aerobic training with standard exercise bike

control group

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Aged 65 and over;
  • Pre-existing diagnosis of Alzheimer's, in mild phase, according to the 2011 criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA);
  • Clinical Dementia Rating Scale CDR = 1;
  • Mini Mental State Examination MMSE \> 19;
  • Functional Ambulation Categories FAC ≥4;
  • Tinetti scale ≥ 20;
  • Presence of a contact family caregiver
  • Reside at home

You may not qualify if:

  • Sensory deficits not compensated by the use of prostheses
  • Psychological and behavioral disorders not compensated by drug treatment
  • Medical contraindication to moderate intensity aerobic exercise

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cognitive Disorders and Dementia (CDCD) -INRCA Hospital

Ancona, 60127, Italy

Location

Related Publications (1)

  • Gambella E, Margaritini A, Benadduci M, Rossi L, D'Ascoli P, Riccardi GR, Pasquini S, Civerchia P, Pelliccioni G, Bevilacqua R, Maranesi E. An integrated intervention of computerized cognitive training and physical exercise in virtual reality for people with Alzheimer's disease: The jDome study protocol. Front Neurol. 2022 Aug 12;13:964454. doi: 10.3389/fneur.2022.964454. eCollection 2022.

MeSH Terms

Conditions

Alzheimer DiseaseDementia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Giuseppe Pelliccioni, MD

    IRCCS INRCA, Ancona, Italy

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2022

First Posted

June 2, 2022

Study Start

June 27, 2022

Primary Completion

June 26, 2023

Study Completion

June 26, 2023

Last Updated

October 26, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations